Union Minister for Commerce and Industry, Piyush Goyal, delivered a compelling address at the 11th edition of the International Exhibition on Pharmaceuticals and Healthcare (iPHEX 2025), underscoring India’s pivotal position in global healthcare. The event, organized by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), served as a platform to discuss India’s role as the “Pharmacy of the World” and the nation’s commitment to providing affordable, high-quality medicines to all. Regulatory convergence, global collaborations, and the enhancement of healthcare systems worldwide were key themes deliberated during the three-day event, emphasizing the need for collective efforts to ensure equitable access to medicines globally.
The inaugural session witnessed notable figures in the pharmaceutical industry shedding light on the significance of regulatory alignment and international partnerships to enhance the accessibility and affordability of quality medicines across borders. The Commerce Minister reiterated the government’s dedication to facilitating market entry, reducing trade barriers, and bolstering the global competitiveness of Indian exporters. This commitment aligns with the vision of ensuring that every individual in India has access to top-notch medications at reasonable prices, reflecting the country’s aspiration to emerge as a self-reliant nation with a robust healthcare infrastructure by 2047.
Dr. Rajeev Singh Raghuvanshi, the Drugs Controller General of India (DCGI), accentuated the shift from volume-based to value-based healthcare solutions, emphasizing India’s focus on developing innovative products that cater to global markets. This transition underscores India’s evolving role in advancing global public health by offering affordable yet innovative healthcare solutions. The statements made by key figures such as Namit Joshi, chairman of Pharmexcil, and Bhavin Mehta, chairman of iPHEX, underscored the substantial growth of India’s pharmaceutical exports, signaling the sector’s resilience, innovation, and expanding global trust.
The multifaceted nature of iPHEX extends beyond being a mere exhibition, evolving into a year-round commitment aimed at bolstering India’s global presence in the pharmaceutical domain. Through strategic initiatives focused on market access expansion, regulatory dialogues, and fostering sustainable trade partnerships, iPHEX serves as a cornerstone in India’s journey towards becoming a frontrunner in global healthcare. The event’s emphasis on empowering Micro, Small, and Medium Enterprises (MSMEs), driving market intelligence, and ensuring compliance underscores the sector’s commitment to sustainable growth and credibility.
Powering Healthcare through Strategic Collaborations
The event’s agenda included a dedicated International Buyer–Seller Meet, an expansive exhibition hosting over 700 stalls, and sector-specific sessions spotlighting India’s prowess in pharmaceutical exports across various segments such as formulations, biosimilars, bulk drugs, and surgical products. iPHEX’s global outreach is exemplified by its engagement with over 5,000 foreign delegates, regulators, and buyers, alongside featuring more than 4,000 Indian exhibitors across prominent cities in India.
Fostering Global Trust and Regulatory Alignment
iPHEX’s impact extends beyond national borders, strengthening India’s reputation as the ‘Pharmacy of the World’ through focused B2B engagements, market access dialogues, and strategic collaborations across key regions. The concurrent Global Regulatory Conclave, organized in collaboration with the Central Drugs Standard Control Organisation (CDSCO), played a pivotal role in promoting good reliance practices, pharmacopoeia convergence, and country-specific regulatory pathways. These discussions are instrumental in fostering international alignment, expediting approvals, and reinforcing global confidence in India’s pharmaceutical landscape.
Driving India’s Pharmaceutical Export Ambitions
Pharmexcil’s proactive role in advocating policy measures, providing regulatory support, and spearheading market development initiatives has significantly contributed to India’s pharmaceutical exports, which currently exceed USD 30 billion annually. iPHEX 2025 serves as a strategic precursor to India’s ambitious goal of becoming a USD 65 billion pharmaceutical export powerhouse by 2030, underscoring the sector’s potential for exponential growth and global leadership.
Conclusion
In conclusion, iPHEX 2025 stands as a testament to India’s unwavering commitment to shaping the future of global healthcare through collaborative efforts, innovation, and regulatory excellence. The event’s focus on empowering domestic pharmaceutical exporters, fostering international partnerships, and driving regulatory harmonization reinforces India’s position as a key player in the global healthcare landscape. By leveraging its strengths in manufacturing high-quality yet cost-effective medications, India is poised to not only meet its domestic healthcare needs but also emerge as a reliable partner in advancing healthcare accessibility worldwide. Through platforms like iPHEX, India continues to pave the way for a healthier, more interconnected global healthcare ecosystem.
Tags: regulatory
Read more on pharmabiz.com